SWM
ALNY icon

SHP Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

SHP Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.7K Sell
112
-2
-2% -$603 ﹤0.01% 643
2026
Q1 		$37.6K Buy
114
+5
+5% +$1.7K ﹤0.01% 562
2025
Q4 		$43.2K Buy
+109
New +$48.2K ﹤0.01% 506

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SHP Wealth Management's ALNY Position: Q2 2026 in Review

SHP Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.8% in Q2 2026, selling an estimated $603 and leaving 112 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #643.

SHP Wealth Management first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $43.2K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SHP Wealth Management held 112 shares of Alnylam Pharmaceuticals worth $33.7K as of Q2 2026.
  • SHP Wealth Management sold 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #643 holding.
  • SHP Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • SHP Wealth Management's Alnylam Pharmaceuticals position peaked at $43.2K in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.